medigraphic.com

2014, Number 3

Next >>

Med Sur 2014; 21 (3)

Estudio de las proteínas 14-3-3 y Tau como biomarcadores en pacientes con enfermedades neurodegenerativas de origen no determinado. Experiencia en el Laboratorio de Patología Clínica de Médica Sur

Briones-Torres CA, Echeverría-Vargas JA, García-Ramos GS, Noffal-Nuño V, Pérez-Jáuregui J

Language: Spanish
References: 15
Page: 116-119
PDF size: 132.25 Kb.


ABSTRACT

Introduction. The gold standard for diagnosis of neurodegenerative diseases of undetermined origin is brain biopsy; however, new techniques have been developed that supports its diagnosis. The detection of protein markers in cerebrospinal fluid, such as 14-3-3 protein, and Tau protein is vital for diagnosis. Objective. Determine the relationship between 14-3-3 and Tau testing in patients referred to the Laboratory of Clinical Pathology with a probable diagnosis of neurodegenerative diseases associated with undetermined origin. Material and methods. It was conducted a retrospective observational-search using the database of the information system of the Laboratory of Clinical Pathology Medical Sur from January 2008 through December 2013 for all requested tests of 14- 3-3 and tau Protein in cerebrospinal fluid. Results. Forty-two of 89 requested tests were positive (14-3-3) (47.2%) of which 69% were women with a mean age of 55.7 years (29-73). 31% were men with a mean age of 59.76 (36-72). The average value of the Tau protein in the positive patients was 9,640 pg/mL (SD ± 18,184 pg/mL). Discussion. In Mexico there is no well-documented information about incidence of these diseases, however, these biochemical markers are very helpful by not being post-mortem procedures. These markers can be elevated in vascular, neoplastic, inflammatory and metabolic diseases of the central nervous system, which are associated with a rapid neuronal destruction. Conclusion. In the context of patients with dementia of undetermined origin, it should be considered the detection of 14-3-3 and Tau protein, since its presence is highly correlated with prion disease.


REFERENCES

  1. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigations sensivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129: 2278.

  2. Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11: 618.

  3. CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease (CJD), 2010.

  4. Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt- Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012; 79: 1499.

  5. Collins S, Boyd A, Fletcher A, et al. Creutzfeldt-Jakob disease: diagnostic utility of 14-3-3 inmunodetection in cerebrospinal fluid. J Clin Neurosci 2000; 7: 203-8.

  6. Preissner CM, Aksamit AJ, Parisi JE, Grebe SK. Development and validation of an immunochemiluminometric assay for 14-3-3 protein. Clin Chem 2009; 55(S6): A199; abstract D-149.

  7. Otto M, Wiltfang J, Tumani H, et al. Elevated levels of tau protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 1997; 225: 210-2.

  8. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58: 192-7.

  9. Hamlin C, Puoti G, Berri S, et al. A comparison of tau protein and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 2012; 79: 547-51.

  10. Velásquez-Pérez L, Rembao-Bojorquez D, Guevara J, et al. Creutzfeldt- Jakob disease in Mexico. Neuropathology 2007; 27: 419- 28.

  11. Bateman D, Hilton D, Love S, Zeidler M, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 18 year old in the UK. Lancet 1995; 346: 1155.

  12. Olov PL. Creuztfeldt-Jakob disease in Sweden. J Neurol Neurosurg Psychiatry 1998; 65: 836-41.

  13. Satoh J, Kuruhara K, Yukitake M, Kuroda Y. The 14-3-3 protein detectable in the cerebrospinal fluid in patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 1999; 41: 216.

  14. Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006; 129: 2278.

  15. Kransnianski A, Schulz-Schaeffer WJ, Kallenberg K, et al. Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain 2006; 129: 2288.




2020     |     www.medigraphic.com